Aespira

Company Overview

Snapshot

Founded in January 2007, Aespira operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on the development of its dry-powder inhaler products.

Business overview

Aespira is a Health Tech & Life Sciences company developing a pipeline of single-use disposable dry-powder inhalers using generic drugs. The company's core technology, ActiveMesh, enables the packaging of dry-powder drugs within a mesh-based system that disperses fine particles through breath-driven beating. Aespira is also developing the resQhaler, a whistle-shaped inhaler designed for effective breath-synchronized drug delivery with audible confirmation, serving patients in the healthcare and consumer markets.

Company Intelligence Q&A

What is Aespira's primary product focus?

Aespira is focused on developing a pipeline of inhaler products that utilize generic drugs, designed to be single-use and disposable.

What is the ActiveMesh technology?

ActiveMesh is Aespira's proprietary technology for packaging dry-powder drugs within a mesh-based system. This technology uses breath-driven beating to sieve and release fine dry-powder particles for inhalation.

What is the resQhaler device?

The resQhaler is a disposable and hygienic whistle-shaped inhaler device developed by Aespira. It uses airflow from the patient's inhalation to efficiently activate the ActiveMesh package, ensuring breath-synchronized drug delivery with audible confirmation.

What problem does Aespira's technology aim to solve?

Aespira's inhalers are designed to prevent contamination, offer simplicity of use for non-trained patients, and facilitate single-dose or non-chronic drug usage.

In which sector does Aespira primarily operate?

Aespira operates primarily in the Health Tech & Life Sciences sector, specifically focusing on medical devices and drug delivery solutions.